India Launches First Biosimilar for World's Top-selling Drug

Dec 11, 2014

Reuters

India-based Cadila Healthcare has launched the first biosimilar version of the world's top-selling anti-inflammatory drug adalimumab -- for a fifth of its U.S. price.

The branded version of adalimumab is sold under the name Humira by U.S.-based AbbVie, and costs $1,000 per vial in the United States. The biosimilar, available in India, will be priced at $200 a vial.

 Read the Reuters press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments